Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective - PubMed
4 hours ago
- #Cancer therapy
- #PARP inhibitors
- #Drug resistance
- PARP inhibitors (PARPi) are used in cancer treatment, leveraging synthetic lethality in cells with homologous recombination repair (HRR) deficiencies.
- Resistance to PARP inhibitors is a significant challenge in cancer therapy, prompting research into overcoming mechanisms of resistance.
- PARP-1 and PARP-2 enzymes play roles beyond DNA repair, including metabolic regulation and disease processes.
- PARP1 is crucial for detecting unligated Okazaki fragments during DNA replication and participates in chromatin remodeling.
- Emerging strategies focus on understanding resistance mechanisms to PARP inhibitors to enhance their clinical efficacy across various cancers.